Our pipeline is currently focused on treating the life-threatening conditions driven by chronic inflammation.

FL-101: Targeting Inflammation-Driven Cancer

We are developing FL-101 as a potentially best-in-class therapy for the treatment of cancers that are driven by inflammation.

Many patients in the United States who are diagnosed with lung cancer have high levels of chronic inflammation.

The pro-inflammatory cytokine, interleukin-1ß (IL-1ß) has been shown to be an independent, causal factor of lung cancer. CANTOS, a major outcomes study published in 2017, evaluated an anti-IL1ß drug that targets the same pathway as Fl-101 in over 10,000 patients. CANTOS supports our theory that reducing IL-1 could result in a significant benefit for patients with lung cancer.

Dose dependent risk reduction with canakinumab in lung cancer mortality incidence of 77% (300mg)

The CANTOS study looked at the effect of IL-1ß mAb in a populaton of 10,061 persons with an MI and CRP > 2. Findings showed remarkable reductions in lung cancer mortality in persons treated with a high dose of Canakinumab.